Medtronic Raises 2027 Outlook Amid Surge in Heart Device Demand

Medtronic has revised its financial forecasts for fiscal 2027 upwards, citing robust demand for its heart devices used in complex cardiovascular procedures. The company now anticipates an annual organic revenue growth of 7.25% to 7.75%, an increase from its previous projection of 6.75% to 7.25%.

CEO Geoff Martha highlighted the broad performance across Medtronic's business segments and the growing impact of new growth platforms as key drivers behind the company's confidence. During a recent earnings call, he emphasized, "What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms."

Strategic Investments and Acquisitions

Medtronic has also announced significant investments to bolster its position in the medical device market. The company is set to invest $80 million in Pi-Cardia, a heart-valve repair device maker, with an option to acquire it for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, gaining distribution rights for a robotic surgical device in select international markets.

Martha noted that the penetration of soft tissue robotic surgery in emerging markets remains below 1%, suggesting substantial growth potential. He described Cornerstone's Sentire device as complementary to Medtronic's existing Hugo device, aligning with the company's strategy to focus on high-growth segments with large patient pools.

Financial Performance and Market Dynamics

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was primarily driven by an 88% surge in its pulsed field ablation portfolio, which is used to treat irregular heart rhythms.

For the quarter, Medtronic posted an adjusted per-share profit of $1.45 on revenues of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Thierry Pieton, Medtronic's Chief Financial Officer, mentioned that the company received tariff refunds that nearly offset the duties paid during the quarter. However, these refunds have not been factored into future financial outlooks.

Martha further elaborated on Medtronic's strategic approach, emphasizing a steady pace of mergers and acquisitions. "We're prioritizing the higher growth segments of medtech that we have confidence are going to be big segments," he stated, underscoring the company's focus on substantial and expanding markets.